When was Dualitas Therapeutics founded?

Dualitas Therapeutics was founded in 2022 and raised its 1st funding round 3 years after it was founded.

Where is Dualitas Therapeutics located?

Dualitas Therapeutics is headquartered in United States.

Is Dualitas Therapeutics a funded company?

Dualitas Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Jul 07, 2025.

When was the latest funding round of Dualitas Therapeutics?

Dualitas Therapeutics' latest funding was a $***** Series A round on Jul 07, 2025, with participation from 6 investors.

Where does Dualitas Therapeutics rank among its competitors?

Dualitas Therapeutics ranks 192nd amongst 1824 active competitors, of which 95 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Dualitas Therapeutics, which secured $65M in Jul, 2025.

Who are the top competitors of Dualitas Therapeutics?

Dualitas Therapeutics' top competitors include AbbVie, Gilead and Amgen. Among them, Dualitas Therapeutics secured the most recent funding round in July, 2025.

Dualitas Therapeutics - 2026 Company Profile, Funding & Competitors

Dualitas Therapeutics is a series A company based in United States, founded in 2022. It operates as a Developer of bispecific antibody therapies using a proprietary discovery engine. Dualitas Therapeutics has raised $65M in funding from Versant Ventures and Qiming. The company has 1824 active competitors, including 95 funded and 202 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.

Company Details

Developer of bispecific antibody therapies using a proprietary discovery engine. The company’s DualScreen platform identifies synergistic co-target combinations for differentiated activity. It focuses on immune and inflammatory diseases, advancing a pipeline of novel bispecific antibodies. These candidates demonstrate enhanced efficacy and immune modulation in preclinical studies. The company offers strategic collaborations for pipeline programs and de novo bispecific antibody identification.

Key Metrics

Founded Year

2022

Location

United States

Stage

Series A

Total Funding

$65M in 1 round

Latest Funding Round

Series A, Jul 07, 2025, $*****

Investors

Versant Ventures & 5 more

Ranked

192^nd among 1824 active competitors

Similar Companies

AbbVie & 1851 more

View Dualitas Therapeutics' full profile

Dualitas Therapeutics has raised a total funding of $65M over 1 round. Its latest funding round was a Series A round on Jul 07, 2025 for $*****. 6 investors participated in its latest round. Dualitas Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Dualitas Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2025	2105649	Series A	3576401	3478740	7181562	5553079

Access funding benchmarks and valuations. Sign up today!

View details of Dualitas Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dualitas Therapeutics include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Dualitas Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 9 others	83/100
2nd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Seaside Private Capital ... & 17 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	79/100
4th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	76/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	74/100
7th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	70/100
9th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
10th	Genentech 1976, San Francisco (United States), Acquired	R&D company focused on manufacturing drugs for multiple therapeutic areas	$72.5M	Ignite 500, The Column Group & 4 others	69/100
192nd	Dualitas Therapeutics 2022, United States, Series A	Developer of bispecific antibody therapies using a proprietary discovery engine	$65M	Versant Ventures, Qiming & 4 others	35/100